Status:
COMPLETED
Surveillance of HCV in Uremics and Linking to Medical Care
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions:
Hepatitis C
Eligibility:
All Genders
18-95 years
Brief Summary
HCV remains to prevail in the uremic patients under hemodialysis. The comprehensive surveillance in the risk population facilitates the link to care for HCV eradication.
Detailed Description
1. Taiwan has the leading prevalence and incidence of end-stage renal disease (ESRD) worldwide. Uremic patients on maintenance hemodialysis (HD) are at great risk for hepatitis C virus (HCV) infection...
Eligibility Criteria
Inclusion
- all uremic patients and medical staffs in the hemodialysis centers
Exclusion
- patients who refuse consents
Key Trial Info
Start Date :
January 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 20 2022
Estimated Enrollment :
2973 Patients enrolled
Trial Details
Trial ID
NCT03803410
Start Date
January 7 2019
End Date
May 20 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807